Aurobindo Pharma zooms on receiving USFDA tentative approval for Dolutegravir

22 Sep 2016 Evaluate

Aurobindo Pharma is currently trading at Rs 842.85, up by 36.70 points or 4.55% from its previous closing of Rs 806.15 on the BSE.

The scrip opened at Rs. 814.90 and has touched a high and low of Rs. 846.90 and Rs. 811.50 respectively. So far 455657 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 891.50 on 30-Dec-2015 and a 52 week low of Rs. 582.00 on 25-Feb-2016.

Last one week high and low of the scrip stood at Rs. 847.50 and Rs. 783.00 respectively. The current market cap of the company is Rs. 49095.73 crore.

The promoters holding in the company stood at 53.79%, while Institutions and Non-Institutions held 34.08% and 12.13% respectively.

Aurobindo Pharma has received tentative approval for Dolutegravir 50mg from US Food & Drug Administration (USFDA). Dolutegravir 50mg is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents.  This important milestone marks the first FDA approval of a generic version of Dolutegravir (DTG), an integrase strand transfer inhibitor recommended for use in treatment-naive patients by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO). Through an innovative collaboration with ViiV and the Clinton Health Access Initiative, Inc (CHAI), the product is expected to be launched in sub-Saharan Africa in late 2016.

The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Tivicay, of ViiV Healthcare. ViiV Healthcare and Aurobindo Pharma signed a licensing agreement in 2014 that allows Aurobindo Pharma to supply Dolutegravir 50mg in 92 licensed countries, following completion of required local regulatory approval processes. The approval of the generic version of DTG shows the commitment towards the larger cause of bringing affordable HIV drugs to millions of people. This is a one-of-its-kind agreement between innovator and generic company where the generic version of the drug will be launched in around three years from the originator product.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments

Aurobindo Pharma Share Price

1211.00 17.95 (1.50%)
18-Dec-2025 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1746.00
Dr. Reddys Lab 1279.60
Cipla 1499.10
Zydus Lifesciences 910.00
Lupin 2119.00
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×